Cancer can run, but it can no
longer hide

Envision cancer sneaking around your immune system by feeding certain cells fatty snacks that make them too sleepy or bossy to help.

That’s what liver cancer does — it hijacks your body’s immune response by jamming immune cells full of fat, turning some into lazy pushovers (called exhausted T cells) and others into overbearing peacekeepers (Tregs) that tell patrolling cancer-killing cells to back off.

But scientists have a new trick up their sleeve to outmaneuver the fatty snack giving — a lab-made antibody called PLT012. It blocks a protein called CD36, which acts like a fatty-acid vacuum cleaner for these sneaky immune cells. When PLT012 steps in, it cuts off the fat supply, helping the immune system to snap out of its slump and start attacking cancer cells again.

In mice — even the tough-to-treat ones — and in human liver-cancer samples in the lab, PLT012 not only boosts cancer-killing immune cells, it also works well alongside other cancer treatments. More notably, it holds strong in high-fat environments that normally limit the effectiveness of treatments.

PLT012 is shaping up to be a potential game changer in liver cancer treatment by targeting the tumor’s tricks and offering the immune system a second wind.

The paper was published in Cancer Discovery.

More like this: Launching medical research

A step forward in targeting tumors

Current immunotherapies often struggle against hard-to-treat tumors with low mutation rates and high variability.

They are hard to target effectively, but new research published in Nature introduces a promising approach by targeting tumor-wide neoantigens — abnormal proteins created due to errors in RNA splicing.

The researchers found that these public neoantigens are common across multiple cancer types, including those more difficult to treat. By mapping RNA splicing patterns
RNA splicing patterns, they identified specific abnormal proteins that are consistently presented by cancer cells and recognized by the immune system.

Targeting these neoantigens could offer a more universal and stable target. This approach could lead to immunotherapies that work across different cancer types, potentially improving outcomes for patients with hard-to-treat tumors.

More on this topic: Launching medical research